

FOR IMMEDIATE RELEASE

Contact: Jackie O'Connor, Compliance Implementation Services

jacquelineoconnor@cis-partners.com, 484-445-7200

www.cis-partners.com

CIS Develops Non-Compliance Monitoring Tool

PHILADELPHIA, PENNSYLVANIA, December 2, 2009 – Compliance Implementation Services (CIS), a consulting firm specializing in compliance strategies has announced CIS ComplianceWatch for biotech and pharmaceutical companies.

“As consultants in the U.S. Commercial Compliance space, we saw a need to help our clients track and capture their non-compliance activities,” said Judy Fox, CIS Commercial Compliance Consultant. “CIS ComplianceWatch is an easy-to-use database designed to help establish internal controls for monitoring non-compliance and disciplinary actions.” “The database offers reporting options to help companies evaluate their entire Compliance Program based on the frequency of certain incidents, or they can evaluate compliance on an individual, district or company-wide basis.”

“A successful Compliance Program should ensure proactive evaluation, identification and mitigation of risk,” said Chris Cobourn, CIS VP, Regulatory Compliance. “By capturing and storing non-compliance issues, such as sales and marketing infractions, HR violations and legal concerns, and the disciplinary actions, organizations will have a better process for managing their compliance risk.”

For a short demo, please <mailto:info@cis-partners.com>

About CIS

Compliance Implementation Services (CIS) is a consulting firm specializing in compliance strategies for pharmaceutical companies, from Global Clinical Research & Development through U.S. Commercial Compliance and Government Programs. Founded in 2004, our deep understanding of industry laws and regulations, innovative and practical applications and custom solutions help our clients establish a “Culture of Compliance” that is both meaningful and practical.

Our experts quickly identify your exposure to compliance risks, help you develop a strategic plan and ensure its implementation and ongoing adherence to legal and regulatory requirements.

###